<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-72310</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Reversal of acenocoumarol anticoagulation with activated factor VII in massive hemorrhage following rupture of a splenic artery pseudoaneurysm</dc:title>
<dc:description xml:lang="en">A 66-year-old man with a metallic valve and undertreatment with acenocoumarol developed hypovolemicshock after rupture of a splenic artery pseudoaneurysm.We managed to reverse anticoagulation within 60 minutesby administering 20 mg of vitamin K and 4.8 mg ofactivated recombinant factor VII. No thromboembolicadverse events were observed. We discuss the pharmacologiceffects of coumarin derivatives and their antagonists,as well as the use of activated factor VII in thereversal of anticoagulation by these drugs(AU)</dc:description>
<dc:creator>Arruga, A. M</dc:creator>
<dc:creator>López, A</dc:creator>
<dc:creator>Reina, M. A</dc:creator>
<dc:creator>Gómez, J. M</dc:creator>
<dc:creator>Galindo, S</dc:creator>
<dc:creator>Varela, C. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Varón de 66 años, con prótesis valvular aórtica metálicaen tratamiento con acenocumarol, que sufrió unarotura de pseudoaneurisma de la arteria esplénica y posteriormentechoque hipovolémico. Se administró 20 mgde vitamina K y 4,8 mg de factor VII activado recombinantelográndose la reversión de la anticoagulación en60 min, sin efectos adversos tromboembólicos clínicamenteevidentes. Analizamos los aspectos farmacológicosde los cumarínicos y sus antagonistas, así como la experienciaexistente en el uso del factor VII activado en lareversión de la anticoagulación por estos fármacos(AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;56(4): 245-248, abr. 2009. tab, fig</dc:source>
<dc:identifier>ibc-72310</dc:identifier>
<dc:title xml:lang="es">Reversión del efecto del acenocumarol con factor VII activado en la hemorragia masiva tras rotura de aneurisma esplénico</dc:title>
<dc:subject>^d3162</dc:subject>
<dc:subject>^d932^s22020</dc:subject>
<dc:subject>^d6622^s22012</dc:subject>
<dc:subject>^d^s22045</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d11269^s22000</dc:subject>
<dc:subject>^d6617^s22057</dc:subject>
<dc:subject>^d4695</dc:subject>
<dc:subject>^d11269^s22073</dc:subject>
<dc:subject>^d6617^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24643^s22000</dc:subject>
<dc:subject>^d78^s22020</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24643^s22073</dc:subject>
<dc:subject>^d78^s22073</dc:subject>
<dc:subject>^d13540^s22053</dc:subject>
<dc:subject>^d7721^s22073</dc:subject>
<dc:subject>^d12795</dc:subject>
<dc:subject>^d7721^s22000</dc:subject>
<dc:subject>^d30856^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200904</dc:date>
</metadata>
</record>
</ibecs-document>
